Boehringer Ingelheim International Gmbh

Ucb Biopharma Sprl

Evotec International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Christopher Francis Palmer

Doris Riether

David S Thomson

Pier Francesco Cirillo

Angela Kay Berry

Monika Ermann

Innocent Mushi

Nigel James Blumire

James Edward Jenkins

Eugene R Hickey

Malcolm Taylor

Renee M Zindell

Zhaoning Zhu

John Robert Porter

Boris Kroeplien

Christopher John Brown

James Andrew Johnson

Timothy John Norman

Pui Leng Loke

Fabien Claude Lecomte

Martin Alexander Lowe

Gareth Neil Brace

Holly Atton

Serge Convers-Reignier

Gregory Foulkes

Muhammed Kamal Uddin

James Lindsay Carr

Prafulkumar Tulshibhai Chovatia

Giancarlo Trani

Daryl Simon Walter

Eugene Richard Hickey

Severine Danielle Jones

Scott Alexander Sadler

Jonathan Paul Shine

Chandana Chowdhury

Mohamad Sabbah

Michael Corr

Marissa Flower

Irena Reboule

Ajay Mandal

Yolanda Pérez-Fuertes

Donald Smyth

Chandana Parke

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R, R, R, R, R, R, R, R, R, X, X, Aand Ahave the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.

Modulators of the integrated stress response pathway

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 

Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Compounds which modulate the CB2 receptor

Compound of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Growing community of inventors

Abingdon, United Kingdom

Christopher Francis Palmer